| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 05/29/2013 | EP2596015A1 Method to improve glycosylation profile and to induce maximal cytotoxicity for antibody |
| 05/29/2013 | EP2596013A1 Nkx2.2 inhibitors as drugs |
| 05/29/2013 | EP2596010A2 Signal biomarkers |
| 05/29/2013 | EP2595662A1 Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile |
| 05/29/2013 | EP2595658A2 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| 05/29/2013 | EP2595657A2 Anti-tumor antigen antibodies and methods of use |
| 05/29/2013 | EP2595655A2 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
| 05/29/2013 | EP2595654A1 Concentrated human immunoglobulin composition |
| 05/29/2013 | EP2595645A2 Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom |
| 05/29/2013 | CN1956738B Antibodies to MAdCAM |
| 05/29/2013 | CN1911965B Binding domain-immunoglobulin fusion proteins |
| 05/29/2013 | CN1829740B Connective tissue growth factor antibodies |
| 05/29/2013 | CN1705491B Optimized Fc variants and methods for their generation |
| 05/29/2013 | CN1582165B Antibodies to CD40 |
| 05/29/2013 | CN103124743A RON binding constructs and methods of use thereof |
| 05/29/2013 | CN103124742A Pharmaceutical compositions and methods of treatment |
| 05/29/2013 | CN103124741A Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 05/29/2013 | CN103123354A Immunodetection assay for mycobacterium tuberculosis complex |
| 05/29/2013 | CN103123353A Immunodetection assay for mycobacterium tuberculosis complex |
| 05/29/2013 | CN103122339A Epitope |
| 05/29/2013 | CN103122032A Anti-mouse-EID1 monoclonal antibody 1G10.7 and hybridoma cell line for secreting same |
| 05/29/2013 | CN103122031A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 05/29/2013 | CN103121959A Compound, nucleic acid compound molecules and nucleic acid complex as well as preparation methods and application thereof |
| 05/29/2013 | CN102585000B Tumor marker CD25 autoantibody and application thereof |
| 05/29/2013 | CN102516388B Anthropogenic LMP1 (latent membrane protein1) extracellular regional antibody for nasopharyngeal carcinoma and application thereof |
| 05/29/2013 | CN102465116B Latex agglutination detection method for porcine circovirus type 2 and application thereof |
| 05/29/2013 | CN102260325B Antibacterial peptide NX-16, and preparation method and application thereof |
| 05/29/2013 | CN102124100B A monoclonal antibody specifically binding to VEGF and the hybridoma secreting same and uses thereof |
| 05/29/2013 | CN101978054B Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 05/29/2013 | CN101891820B Humanized anti-human von willebrand disease factor monoclonal antibody and application thereof |
| 05/29/2013 | CN101636168B Sp35 antibodies and uses thereof |
| 05/29/2013 | CN101374863B Immunoglobulins directed against NOGO |
| 05/29/2013 | CN101189028B Identification and engineering of antibodies with variant Fc regions and methods of using the same |
| 05/29/2013 | CN101023102B Anti-OX40L antibodies |
| 05/28/2013 | US8450470 Use to faciliate drug delivery of other drugs, or treat glycosaminoglycan associated pathologies, such as scarring, spinal cord injury, glaucoma, and cosmetic treatments |
| 05/28/2013 | US8450465 Methods of isolating peptides using surface-free affinity purification |
| 05/28/2013 | US8450464 Human monoclonal antibodies that bind CXCR4 |
| 05/28/2013 | US8450463 Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method |
| 05/28/2013 | US8450462 Compound |
| 05/28/2013 | US8450461 Risperidone immunoassay |
| 05/28/2013 | US8450457 T1R taste receptors and genes encoding same |
| 05/28/2013 | US8450073 Stabilizing agents and capture ligands for use in assays measuring analyte concentrations |
| 05/28/2013 | US8450067 Method for obtaining anti-idiotype antibodies |
| 05/28/2013 | US8449889 Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| 05/28/2013 | US8449888 Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| 05/28/2013 | US8449885 Anti-VEGF antibodies |
| 05/28/2013 | US8449884 Clotting factor-fc chimeric proteins to treat hemophilia |
| 05/28/2013 | US8449864 Neurotensin as a marker and therapeutic target for sepsis |
| 05/28/2013 | CA2563260C Methods of treating autoimmune and inflammatory diseases |
| 05/28/2013 | CA2542192C Look-through mutagenesis |
| 05/28/2013 | CA2517258C Recombinant measles virus comprising dengue or west nile virus polynucleotides, and their use in vaccinal and therapeutic applications |
| 05/28/2013 | CA2514794C Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 05/28/2013 | CA2502904C Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| 05/28/2013 | CA2494372C Antibodies that immunospecifically bind to trail receptors |
| 05/28/2013 | CA2489595C Recombination of nucleic acid library members |
| 05/28/2013 | CA2476773C Monoclonal antibodies against extracellular loops of c5ar |
| 05/28/2013 | CA2473144C Protein purification |
| 05/28/2013 | CA2443372C Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides |
| 05/28/2013 | CA2440831C Combination therapy using cd40 and cd20 ligands |
| 05/28/2013 | CA2434802C Isolating cells expressing secreted proteins |
| 05/28/2013 | CA2427902C Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/28/2013 | CA2412239C Cytokine receptor zcytor17 |
| 05/28/2013 | CA2323210C Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 05/28/2013 | CA2285692C Enhancement of immune response using targeting molecules |
| 05/28/2013 | CA2280997C Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| 05/23/2013 | WO2013075048A1 Methods of treating epidermal growth factor deletion mutant viii related disorders |
| 05/23/2013 | WO2013074840A1 Treatment of dry age related macular degeneration |
| 05/23/2013 | WO2013074569A1 Anti il-36r antibodies |
| 05/23/2013 | WO2013074557A1 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| 05/23/2013 | WO2013072714A1 Antibodies for molecular imaging of vulnerable plaques in atherosclerosis |
| 05/23/2013 | WO2013072523A1 Bi-specific antibodies for medical use |
| 05/23/2013 | WO2013072514A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| 05/23/2013 | WO2013072513A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| 05/23/2013 | WO2013072512A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
| 05/23/2013 | WO2013072511A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| 05/23/2013 | WO2013072510A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| 05/23/2013 | WO2013072438A1 Antibodies for molecular imaging of vulnerable plaques in atherosclerosis |
| 05/23/2013 | WO2013072415A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | WO2013072406A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | WO2013072381A1 Diagnosis of sepsis and systemic inflammatory response syndrome |
| 05/23/2013 | WO2013048153A3 Binding molecule having influenza a virus-neutralizing activity produced from human b cell |
| 05/23/2013 | WO2013046704A3 THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
| 05/23/2013 | WO2012143561A3 Analyzing the expression of biomarkers in cells with clusters |
| 05/23/2013 | WO2008147883A8 Prevention and treatment of complement-associated eye conditions |
| 05/23/2013 | US20130133091 Human Monoclonal Antibodies To Programmed Death 1 (PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone Or In Combination With Other Immunotherapeutics |
| 05/23/2013 | US20130131322 Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having ras gene mutation |
| 05/23/2013 | US20130131320 Highly-functional mutant of humanized anti-egfr antibody variable region |
| 05/23/2013 | US20130131319 Antibodies with modified affinity to fcrn that promote antigen clearance |
| 05/23/2013 | US20130131318 Single unit antibody purification |
| 05/23/2013 | US20130130388 Methods of Modifying Eurakyotic Cells |
| 05/23/2013 | US20130130379 Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| 05/23/2013 | US20130130316 Cell cultivation process |
| 05/23/2013 | US20130130315 Fusion protein |
| 05/23/2013 | US20130130233 Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| 05/23/2013 | US20130129766 Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| 05/23/2013 | US20130129753 Cytotoxic peptides and antibody drug conjugates thereof |
| 05/23/2013 | US20130129752 Targeted delivery to leukocytes using protein carriers |
| 05/23/2013 | US20130129749 Humanized anti-egfl7 antibodies and methods using same |
| 05/23/2013 | US20130129746 Anti-serum albumin binding variants |
| 05/23/2013 | US20130129745 Anti-fxi antibodies and methods of use |